Index Pharmaceuticals Ab

Charlotte Admyre

Arezou Zargari

Oliver Von Stein

Petra Von Stein

Lars-Göran Axelsson

Peter Zerhouni

Nicolai Kouznetzov

Thomas Knittel

Pernilla Sandwall

Nikolai Kouznetsov

Lars-Goran Axelsson

The present invention provides an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3&#x2032; (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 100 mg to 350 mg of said oligonucleotide are administered to the subject on at least four separate occasions, wherein the separate occasions are each a week apart.

Therapy

The present invention provides an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3&#x2032; (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in a human subject, wherein individual doses of from 150 mg to 350 mg of said oligonucleotide are administered to the subject on at least two separate occasions, wherein said separate occasions are 3 weeks apart.

Cobitolimod for use in the treatment of inflammatory bowel disease

Methods for reducing recruitment, migration, or both recruitment and migration of polymorphonuclear cells to a site of inflammation in an organ of a human patient comprise administering locally to the organ or systemically to the patient in need thereof an isolated oligonucleotide selected from the group consisting of SEQ ID NO: 8 (IDX9059); SEQ ID NO: 14 (IDX9052); SEQ ID NO: 7 (IDX9054); SEQ ID NO: 6 (IDX9045); SEQ ID NO: 1 (IDX9005); SEQ ID NO: 9 (IDX9074); SEQ ID NO: 3 (IDX9022); SEQ ID NO: 2 (IDX9010); SEQ ID NO: 4 (IDX9030); and SEQ ID NO: 13 (IDX0150).

Compounds and methods for reducing the recruitment and/or migration of polymorphonuclear cells

A method of treating chronic active ulcerative colitis in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, comprises administering to a patient in need thereof an effective exposure of an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3&#x2032; (SEQ ID NO.2), wherein at least one CG dinucleotide is unmethylated. The oligonucleotide is not administered with corticosteroids or glucocorticosteroids.

Method for prevention of colectomy

The present invention relates to methods of identifying oligonucleotides capable of modulating the immune system in a mammalian subject, comprising analysis of which tertiary structural type said oligonucleotide adopts, in phosphate-buffered saline solution. Further, the invention provides oligonucleotides identifiable by the methods of the invention and to their use in methods of treating diseases, such as inflammatory diseases, autoimmune diseases, infectious diseases, neurodegenerative diseases and cancer.

Method for identifying biologically active oligonucleotides capable of modulating the immune system

The present invention relates to methods of preventing or reducing the need of colectomy. In particular, the present invention relates to an oligonucleotide, for use in the treatment of an inflammatory bowel disease, such as ulcerative colitis (UC) or Crohn's disease, in a subject that is refractory or responds insufficiently or is intolerant to anti-inflammatory therapy, wherein said oligonucleotide is repetitively administered as a single exposure.

A therapeutically effective amount of an oligonucleotide is capable of influencing the properties and behavior of polymorphonuclear cells, e.g. suppressing endothelial adhesion and transmigration of said cells, and through this mechanism reduce the recruitment and/or migration of polymorphonuclear cells to a site of inflammation.

Growing community of inventors

Vendelsö, Sweden

Charlotte Admyre